MedTrace Logo

Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

NCT01989520 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-06-25

No results posted yet for this study

Summary

Study to investigate relative bioavailability of up to five different formulations of AZD5069

Conditions

  • Uncontrolled and Persistent Asthma

Interventions

DRUG

Phase IIb formulation

Single oral dose 45mg AZD5069

DRUG

Putative phase III formulation

Single oral dose 45mg AZD5069

DRUG

Slow dissolution variant 1

Single oral dose 45mg AZD5069

DRUG

Slow dissolution variant 2

Single oral dose 45mg AZD 5069

DRUG

Test treatment E

Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069

Sponsors & Collaborators

Principal Investigators

  • Olufeyikemi Oluwayi, MD · Quintiles London UK

  • Bengt Larssons, MD · Astrazeneca Mölndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01989520 on ClinicalTrials.gov